Johnson Sandra M, Chavda Rajeev, DuBois Janet C
Johnson Dermatology, Fort Smith, AR, USA.
Galderma SA, La Tour-de-Peilz, Switzerland.
Dermatol Ther (Heidelb). 2020 Oct;10(5):1165-1173. doi: 10.1007/s13555-020-00417-4. Epub 2020 Jul 4.
There is a paucity of literature covering patient-reported outcomes of treatments for truncal acne. Trifarotene 50 μg/g cream is a novel retinoid molecule approved for once-daily topical treatment of facial and truncal acne vulgaris. As physicians are starting to gain real-world experience with this retinoid treatment, their access to reporting from the patient's perspective provides a valuable adjunct to the pivotal studies. We report a case series of three subjects with moderate facial and truncal acne treated with trifarotene 50 μg/g cream on the face, shoulders, upper back and upper anterior chest for 12 weeks and evaluated by satisfaction questionnaires. This case series illustrating the treatment of facial and truncal acne with trifarotene 50 μg/g cream, in the form of real-world data, describes high overall satisfaction and excellent tolerability to support the use of this new retinoid molecule in the treatment of acne vulgaris on both the face and trunk.
关于躯干痤疮治疗的患者报告结局的文献较少。50μg/g的曲法罗汀乳膏是一种新型维甲酸类分子，已获批用于寻常性面部和躯干痤疮的每日一次局部治疗。随着医生开始积累这种维甲酸治疗的实际经验，从患者角度获取报告可为关键研究提供有价值的补充。我们报告了一个病例系列，3名患有中度面部和躯干痤疮的受试者，在面部、肩部、上背部和前胸使用50μg/g的曲法罗汀乳膏治疗12周，并通过满意度问卷进行评估。这个病例系列以实际数据的形式说明了50μg/g的曲法罗汀乳膏对面部和躯干痤疮的治疗情况，描述了较高的总体满意度和良好的耐受性，以支持这种新的维甲酸类分子用于治疗面部和躯干的寻常性痤疮。
